Menzella, Francesco http://orcid.org/0000-0003-3950-5789
Bargagli, Elena
Aliani, Maria
Bracciale, Pietro
Brussino, Luisa
Caiaffa, Maria Filomena
Caruso, Cristiano
Centanni, Stefano
D’Amato, Maria
Del Giacco, Stefano
De Michele, Fausto
Di Marco, Fabiano
Pastorello, Elide Anna
Pelaia, Girolamo
Rogliani, Paola
Romagnoli, Micaela
Schino, Pietro
Senna, Gianenrico
Vultaggio, Alessandra
Simoni, Lucia
Ori, Alessandra
Boarino, Silvia
Vitiello, Gianfranco
Altieri, Elena
Canonica, Giorgio Walter
Funding for this research was provided by:
astrazeneca spa italy
Article History
Received: 6 August 2021
Accepted: 1 February 2022
First Online: 19 February 2022
Declarations
:
: This study was conducted in accordance with the ethical principles laid down in the Declaration of Helsinki and to the regulations and guidelines governing medical practice and ethics in Italy. All patients provided informed consent before being enrolled in the study. Ethical approval was provided by the ethics committees/institutional review boards at each participating site.
: Not applicable.
: FM declares research fundings as Principal investigator by AstraZeneca, Chiesi Farmaceutici, Novartis, Sanofi; fees as speaker/lecturer by AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, Novartis, Sanofi; EB has nothing to declare; MA has nothing to declare; PB has nothing to declare; LB has nothing to declare; MFC has nothing to declare; CC has nothing to declare; SC declares grants and/or personal fees from AstraZeneca, Boheringer Ingelheim, Chiesi, Glaxo Smith Kline, Guidotti, Menarini, Novartis, Valeas; MDA has nothing to declare; SDG received grants and/or personal fees from AstraZeneca, Chiesi, Glaxo Smith Kline, Menarini, Novartis; FDM has nothing to declare; FDM has received lectures fees at national and international meetings and consultancy fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dompe, Guidotti/Malesci, GlaxoSmithKline, Menarini, Novartis, and Zambon; EAP has nothing to declare; GP has received lecture fees and consultancy fees from Alfasigma, AstraZeneca, Chiesi, GlaxoSmithKline, Guidotti-Malesci, Menarini, Mundipharma, Novartis, Sanofi, Zambon; PR has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, her department has received funding from Almirall, Boehringer Ingelheim, Chiesi, Novartis, and Zambon; MR declares grants and personal fees from Boehringer Ingelheim, Roche, AstraZeneca, Novartis, Chiesi, GSK, Menarini, Guidotti, AlfaSigma, Zambon; PS has nothing to declare; GS has nothing to declare; AV received payment for lectures and consultant arrangements from Novartis, GlaxoSmithKline, Teva, AstraZeneca; LS and AO are a employees of MediNeos Observational Research; SB and GV are AstraZeneca employees; EA has nothing to declare; GWC has received grant/research support from Boehringer Ingelheim, ALK, and Stallergenes, and honoraria or consultation fees from Menarini, GSK, Sanofi, Teva, Hal, AstraZeneca, and Novartis.